Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Nuvelo Inc (ABIO)  
$0.33 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 14,410,000
Market Cap: 4.80(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.3333 - $0.3333
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Diagnostic Substances

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 183,171
Total Buy Value $0 $0 $0 $421,674
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 8
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 115
  Page 5 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Selby Brian L. VP, Finance   •       –      –    2015-03-02 4 AS $0.71 $800 D/D (1,125) 33,441     -
   Ozeroff Christopher David S.V.P., General Counsel   •       –      –    2015-02-12 4 A $0.00 $0 D/D 24,050 150,787     -
   Keuer Thomas A Chief Operating Officer   •       –      –    2015-02-12 4 A $0.00 $0 D/D 25,350 126,626     -
   Bristow Michael R President and CEO   •       •      –    2015-02-12 4 A $0.00 $0 D/D 48,100 340,725     -
   Selby Brian L. VP, Finance   •       –      –    2015-02-12 4 A $0.00 $0 D/D 23,400 34,566     -
   Mccormack Riley 10% Owner   –       –       •   2015-01-16 4 S $0.75 $75,000 I/I (100,000) 2,100,000     -
   Mccormack Riley 10% Owner   –       –       •   2015-01-15 4 S $0.75 $93,750 I/I (125,000) 2,200,000     -
   Mccormack Riley 10% Owner   –       –       •   2015-01-14 4 S $0.79 $98,750 I/I (125,000) 2,325,000     -
   Mccormack Riley 10% Owner   –       –       •   2015-01-07 4 S $0.87 $174,000 I/I (200,000) 2,450,000     -
   Mccormack Riley 10% Owner   –       –       •   2015-01-06 4 S $0.92 $184,000 I/I (200,000) 2,650,000     -
   Mccormack Riley 10% Owner   –       –       •   2015-01-05 4 S $0.97 $145,500 I/I (150,000) 2,850,000     -
   Selby Brian L. VP, FinanceOfficer   •       –      –    2014-12-30 3 IO $0.00 $0 D/D 0 11,166     -
   Keuer Thomas A Chief Operating OfficerOfficer   •       –      –    2014-12-30 3 IO $0.00 $0 D/D 0 101,276     -
   Bristow Michael R President and CEO   •       •      –    2014-09-18 4 AS $1.30 $18,009 D/D (13,853) 292,625     -
   Wheeler Patrick M Chief Financial Officer   •       –      –    2014-09-18 4 AS $1.31 $10,802 D/D (8,246) 101,510     -

  115 Records found
  1  2  3  4  5    
  Page 5 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed